New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
08:03 EDTKMDAKamada completes enrollment in KamRAB U.S. clinical trial
Kamada announced that it has completed enrollment in its U.S. Phase 2/3 clinical trial of KamRAB as a post-exposure prophylaxis for rabies. Kamada has a strategic agreement with Kedrion for the clinical development and marketing of KamRAB in the U.S. The Phase 2/3 clinical trial is a prospective, randomized, double-blind, non-inferiority study of 118 healthy subjects to evaluate the safety and effectiveness of KamRAB. The study assesses whether KamRAB interferes with the development of self-active antibodies. The primary and secondary endpoints of this study are pharmacokinetic parameters of anti-rabies IgG levels in serum at different time points. In addition, safety and tolerability are assessed. The company said, "We look forward to completing this pivotal study in the coming months and, pending a favorable outcome, to filing a submission for approval with the FDA thereafter.
News For KMDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:08 EDTKMDASource Capital Group to hold a conference
Subscribe for More Information
February 2, 2016
07:18 EDTKMDAKamada reports Q4 EPS 3c, one estimate (9c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use